Bryan Johnson and the Business of Not Dying: Inside Blueprint and the Longevity Movement

Bryan Johnson is the American entrepreneur who sold his payments company and then turned his own body into a public laboratory. He founded Braintree in 2007, bought Venmo for $26.2 million in 2012, and sold the combined business to PayPal for $800 million in 2013, reportedly taking home more than $300 million himself, according to his Wikipedia profile. In October 2021 he announced Project Blueprint, an attempt to slow and measure his own aging that he says cost roughly $2 million a year at its peak. Born in August 1977, Johnson, now 48, has become the most visible face of what he calls the “Don’t Die” movement.

From payments founder to professional test subject

Johnson’s pivot was funded by the PayPal exit. He later founded Kernel, a neurotechnology company, and OS Fund, a venture firm, before centering his public life on longevity. Project Blueprint, announced on October 13, 2021, set an explicit and deliberately provocative goal: to reduce the biological age of his organs and, in his framing, to make “death an option,” per Wikipedia. The pitch is unusual because Johnson is both the experimenter and the experiment. A team of physicians designs the protocol, and Johnson runs it on himself while publishing the data.

A measured-everything protocol, and a shrinking pill count

The headline number is the spending. Johnson has said the protocol cost about $2 million annually in 2023 while tracking more than 100 health measurements, from organ-specific imaging to blood panels and sleep metrics, according to Wikipedia. The regimen is built on a strict plant-forward diet, an early and consistent sleep schedule, daily exercise, and a large supplement stack. Notably, the stack has shrunk. Johnson reduced his daily supplement count from 111 to around 30 by March 2026, Wikipedia reports, a quiet admission that more is not always better. Most of the interventions that researchers actually endorse, such as sleep, diet, and exercise, are the cheap parts of the program, not the expensive scans.

What is evidence-based, and what is self-experiment

This is the crucial distinction, and Johnson’s own results illustrate it. The foundations of his protocol, regular exercise, good sleep, and a careful diet, are among the few aging-related interventions with broad scientific support. The exotic add-ons are far shakier. Longevity researcher Andrew Steele has stated flatly that “there is no medical intervention that is proven to extend human life by targeting ageing itself,” in Scientific American. Aging biologist Matt Kaeberlein, quoted in the same piece, describes a “signal-to-noise problem,” where preliminary findings get amplified long before clinical validation. Much of what Johnson does sits squarely in the unproven column, and he generally presents his personal readouts as his own data rather than as settled science. For the wider drug picture, see our explainer on longevity drugs like rapamycin, metformin and senolytics.

The rapamycin and plasma episodes he later dropped

Two of Johnson’s most-discussed experiments are notable precisely because he abandoned them. He took rapamycin, an immunosuppressant with striking lifespan-extension data in mice, for nearly five years before stopping in September 2024. Johnson said the drug brought intermittent skin and soft-tissue infections, elevated glucose, lipid abnormalities and a higher resting heart rate, and that the benefits did not justify the side effects, as reported by Men’s Fitness. He also cited research suggesting rapamycin may accelerate certain epigenetic aging markers in humans. If you want to understand how those clocks work, read our guide to epigenetic clocks and biological age testing.

The plasma chapter was more controversial. In 2023, Johnson ran what he called a multigenerational plasma exchange, receiving a one-liter plasma transfusion from his teenage son while donating his own to his then-70-year-old father, Fortune reported. Johnson later said he saw “no benefits” from the transfusions and discontinued the practice. The U.S. Food and Drug Administration has warned that young-plasma infusions marketed for anti-aging are without proven benefit and may be harmful, per Scientific American.

Blueprint the movement, Blueprint the business

Johnson has turned the protocol into a commercial product line. In 2024 he launched a consumer brand selling Blueprint supplements, olive oil, protein and other staples, and the company raised $60 million from investors including Kim Kardashian and the Winklevoss twins, according to Wikipedia. The cultural reach grew further with the Netflix documentary “Don’t Die: The Man Who Wants to Live Forever,” directed by Chris Smith (of “Tiger King” and “Fyre”) and released on January 1, 2025, Variety reported. Critics were split: some felt the film humanized Johnson, while TheWrap argued it was too credulous toward his claims. That tension, between data and marketing, runs through the entire enterprise.

Johnson is not alone in this space, and his prominence has helped pull serious money and serious scientists toward longevity. For context on the broader field, see our roundup of longevity founders to watch. The honest reading of Johnson is that he has popularized basic health discipline and rigorous self-tracking, while also normalizing experimental interventions that the evidence does not yet support. He is, by his own account, a test subject, and a test subject is not a clinical trial.

FAQ

Did Bryan Johnson really reverse his aging?

Johnson reports improvements on various biomarkers, but those are self-tracked personal results, not peer-reviewed proof of life extension. Researchers stress that no intervention is proven to extend human lifespan by targeting aging itself, per Scientific American.

Why did he stop taking rapamycin and using plasma?

He says rapamycin caused side effects, including infections and metabolic changes, that outweighed any benefit, and that he saw no measurable benefit from plasma transfusions, according to Men’s Fitness and Fortune.

Is Blueprint a science project or a company?

Both. It began as Johnson’s personal protocol and now also operates as a consumer brand that raised $60 million in 2024, Wikipedia notes. Readers should weigh the commercial incentive when assessing health claims.

Sources

1. Wikipedia, Bryan Johnson
2. Scientific American, Silicon Valley’s longevity biohackers are engaged in a dangerous experiment
3. Fortune, Bryan Johnson admits he saw ‘no benefits’ after injecting his son’s plasma
4. Men’s Fitness, Biohacker Bryan Johnson stopped taking this anti-aging drug for adverse effects
5. Variety, ‘Don’t Die’: Netflix doc chronicles Bryan Johnson’s anti-aging crusade
6. Wikipedia, Don’t Die: The Man Who Wants to Live Forever